Table 1.
Demographic and neuropsychologic test results for each patient group
| A−/T−/N+ | A+/T−/N+ | All T−/N+ | A+/T+/N+ | P-value | |
|---|---|---|---|---|---|
| (n = 4) | (n = 5) | (n = 9) | (n = 15) | ||
| Sex, % male | 0 | 80 | 44 | 47 | 0.9158 |
| Education (Q1, Q3) | 15 (13.5, 16) | 16 (16, 16) | 16 (14, 16) | 16 (14, 19.5) | 0.3397 |
| Age at PET (Q1, Q3) | 82 (79, 85) | 85 (81, 89) | 85 (79, 86) | 76 (75, 78.5) | 0.0031 |
| APOE genotype | |||||
| ApoE4 carriers, (%)a | 1/4 (25) | 1/3 (33) | 2/7 (28) | 9/13 (67) | 0.1597 |
| Global function | |||||
| MoCA (Q1, Q3) | 17 (13.5,19) | 16 (13, 16) | 16 (13, 19) | 15 (8.5, 21) | 0.7879 |
| MMSE (Q1, Q3) | 22 (16.5, 22.75) | 24 (24, 26) | 24 (22, 25) | 22 (19, 25) | 0.6969 |
| CDR Global (Q1, Q3) | 1 (0.75, 1) | 0.5 (0.5, 1) | 0.75 (0.5, 1) | 1 (0.5, 1) | 0.312 |
| CDR Sum of Boxes (Q1, Q3) | 6 (4.5,6.5) | 2.5 (0.5, 5.5) | 4.25 (2, 6) | 4.5 (3.5, 9) | 0.2559 |
| Language function | |||||
| Multilingual Naming Test, z-score (Q1, Q3) | 0.25 (0, 0.5) | −3.3 (−4.9, −0.2) | −0.18 (−3.7, 0.1) | −2.15 (−3.1, −1.3) | 0.4088 |
| Category Fluency, z-score (Q1, Q3) | −1.71 (−2, −1.7) | −1.85 (−2, −1.34) | −1.78 (−2.1, −1.6) | −1.76 (−2.4, −1.1) | 0.9039 |
| Memory function | |||||
| Craft Story, Immediate Recall, z-score (Q1, Q3) | −1.93 (−2.2, −1.5) | −2.72 (−3, −2.1) | −2.29 (−2.8, −1.7) | −2.27 (−2.5, −1.6) | 0.8404 |
| Craft Story, Delayed Recall, z-score (Q1, Q3) | −2.35 (−2.8, −2) | −2.72 (−2.8, −2.5) | −2.62 (−2.8, −2.2) | −2.93 (−3.2, −2.5) | 0.1483 |
| Benson Diagram, Delayed Recall, z-score (Q1, Q3) | −2.82 (−3.2, −2.5) | −2.36 (−3.2, −2.1) | −2.59 (−3.3, −2.2) | −3.48 (−3.7, −2.9) | 0.1087 |
| Attention/Executive function | |||||
| Digit Span, Forward, z-score (Q1, Q3) | −0.59 (−0.84, −0.37) | 0.12 (−0.11, 0.26) | −0.36 (−0.4, 0.1) | −0.41 (−0.9, 0.2) | 0.6983 |
| Trial Making Test Part B, z-score (min, max) | −3.86b | −1.08 and 0.00b | −1.08 (−3.9, 0.0) | −1.02 (−5.3, 0.29) | 1 |
| Visuospatial function | |||||
| Benson Diagram, Copy, z-score (Q1, Q3) | 1.13 (−0.8,1.3) | −1.00 (−2.6, 1) | 0.01 (−2.6, 1.1) | −0.40 (−1.9, −0.4) | 0.5631 |
| Molecular imaging | |||||
| Amyloid SUVR | 1.33 (1.30, 1.35) | 2.01 (1.57, 2.03) | 1.54 (1.34, 2.01) | 2.71 (2.56, 2.84) | 0.0017 |
| Tau SUVR | 1.20 (1.14, 1.26) | 1.26 (1.24, 1.29) | 1.26 (1.14, 1.27) | 1.62 (1.59, 1.94) | <0.0001 |
Demographic and neuropsychological test results for each patient group. Z-scores, corrected for age, sex, and education, are shown for individual cognitive domains. Median and interquartile range (Q1, Q3) are reported unless stated otherwise. Each cognitive domain is tested in accordance with the Uniform Data Set version 3.0 neuropsychological battery. The first two columns report results for tau-negative participants split by amyloid status. These are combined in column 3 and compared with tau-positive participants. P-values shown are for the tau-positive versus tau-negative group comparison.
aTwo patients from the tau PET negative (T−/N+) group and two patients from the tau PET positive (T+/N+) group were missing APOE genotyping.
bMissing for multiple participants, participant level result(s) shown.
MMSE = Mini-Mental State Examination; A+ = amyloid-PET positive; A− = amyloid-PET negative; MoCA = Montreal Cognitive Assessment; T−/N+ = tau-PET negative, neurodegeneration positive; T+/N+ = tau-PET positive, neurodegeneration positive.